Home › Ovarian Cancer › South Dakota
Ovarian Cancer clinical trials in South Dakota
16 studies for Ovarian Cancer are looking for participants at sites in South Dakota.
Cities in South Dakota
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Avera Medical Group, Sioux Falls
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0132 - Avera Cancer Institute, Sioux Falls
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Sanford Cancer Center /ID# 274901, Sioux Falls
- Avera Cancer Institute - Sioux Falls /ID# 276226, Sioux Falls
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Avera Cancer Institute - Sioux Falls /ID# 278627, Sioux Falls
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Sanford Health, Sioux Falls
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT06915025Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Sanford Cancer Center-Sioux Falls, Sioux Falls
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Avera Cancer Institute Sioux Falls, Sioux Falls
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT06787612A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0112, Sioux Falls
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 12, 2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Sanford Cancer Center Gynecologic Oncology, Sioux Falls
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 28, 2026 · NCT06161025A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Avera Medical Group Gynecologic, Sioux Falls
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- and 2 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT05142033From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.